Avalo Therapeutics, Inc.
AVTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $441 | $1,924 | $18,051 | $5,398 |
| % Growth | -77.1% | -89.3% | 234.4% | – |
| Cost of Goods Sold | -$366 | $1,284 | $3,434 | $1,491 |
| Gross Profit | $807 | $640 | $14,617 | $3,907 |
| % Margin | 183% | 33.3% | 81% | 72.4% |
| R&D Expenses | $52,078 | $13,784 | $31,308 | $59,835 |
| G&A Expenses | $16,452 | $10,267 | $20,635 | $23,001 |
| SG&A Expenses | $17,241 | $10,300 | $20,711 | $24,658 |
| Sales & Mktg Exp. | $789 | $33 | $76 | $1,657 |
| Other Operating Expenses | $0 | $3,907 | $38 | $1,548 |
| Operating Expenses | $69,319 | $27,991 | $52,057 | $86,041 |
| Operating Income | -$68,512 | -$27,351 | -$37,440 | -$82,134 |
| % Margin | -15,535.6% | -1,421.6% | -207.4% | -1,521.6% |
| Other Income/Exp. Net | $33,497 | -$4,179 | -$4,190 | -$2,411 |
| Pre-Tax Income | -$35,015 | -$31,530 | -$41,630 | -$84,545 |
| Tax Expense | $114 | $14 | $28 | -$196 |
| Net Income | -$35,129 | -$31,544 | -$41,658 | -$84,376 |
| % Margin | -7,965.8% | -1,639.5% | -230.8% | -1,563.1% |
| EPS | -4.32 | -113.58 | -1,062.65 | -2,330.66 |
| % Growth | 96.2% | 89.3% | 54.4% | – |
| EPS Diluted | -3.26 | -113.58 | -1,062.65 | -2,330.66 |
| Weighted Avg Shares Out | 8,129 | 278 | 39 | 36 |
| Weighted Avg Shares Out Dil | 10,784 | 278 | 39 | 36 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,317 | $0 | $0 | $0 |
| Interest Expense | $0 | $3,417 | $4,170 | $2,391 |
| Depreciation & Amortization | $169 | $158 | $166 | $1,657 |
| EBITDA | -$68,343 | -$23,286 | -$37,274 | -$80,477 |
| % Margin | -15,497.3% | -1,210.3% | -206.5% | -1,490.9% |